{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:13:14Z","timestamp":1767625994819,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brain Cells"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002814","name":"Cederroth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002814","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cyberonics"},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EpiQ"},{"name":"Forest Pharmaceuticals"},{"name":"Genaissance"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innapharma"},{"DOI":"10.13039\/501100004120","name":"Lichtwer Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neuronetics"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Organon"},{"name":"Pamlab"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PGx Health"},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"NARSAD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009654","name":"Sepracor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012224","name":"Stanley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012224","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Targacept"},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wyeth-Ayerst Laboratories"},{"name":"Massachusetts General Psychiatry Academy"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jad.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T20:50:10Z","timestamp":1549745410000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine"],"prefix":"10.1016","volume":"250","author":[{"given":"A.A.","family":"Nierenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Loft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.K.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","series-title":"Diagnostic and Statistical Manual of Mental Disorders","key":"10.1016\/j.jad.2019.02.006_bib0001"},{"key":"10.1016\/j.jad.2019.02.006_bib0002","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.02.006_bib0003","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.02.006_bib0004","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1017\/S0033291712002085","article-title":"Cognitive impairment in euthymic major depressive disorder: a meta-analysis","volume":"43","author":"Bora","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2019.02.006_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cct.2006.10.010","article-title":"Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study","volume":"28","author":"Collie","year":"2007","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jad.2019.02.006_bib0006","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1017\/S0033291710001911","article-title":"Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study","volume":"41","author":"Conradi","year":"2011","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2019.02.006_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1092852913000643","article-title":"Patient-centered assessment of cognitive symptoms of depression","volume":"21","author":"Fehnel","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2019.02.006_bib0008","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence","volume":"48","author":"Frank","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.02.006_bib0009","series-title":"ECDEU Assessment Manual For Psychopharmacology Revised","first-page":"217","article-title":"Clinical global impressions","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2019.02.006_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2019.02.006_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1017\/S1092852915000553","article-title":"Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis","volume":"21","author":"Jacobsen","year":"2016","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2019.02.006_bib0012","first-page":"115","article-title":"Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study","volume":"2","author":"Kaser","year":"2017","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.jad.2019.02.006_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.02.006_bib0014","doi-asserted-by":"crossref","first-page":"A330","DOI":"10.1016\/j.jval.2013.08.046","article-title":"Psychometric Validation of Perceived Deficits Questionnaire - Depression (PDQ-D) in Patients with Major Depressive Disorder (MDD)","volume":"16","author":"Lam","year":"2013","journal-title":"Value in Health"},{"year":"1983","series-title":"Neuropsychological Assessments","author":"Lezak","key":"10.1016\/j.jad.2019.02.006_bib0015"},{"key":"10.1016\/j.jad.2019.02.006_bib0016","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/npp.2015.52","article-title":"A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder","volume":"40","author":"Mahableshwarkar","year":"2015","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2019.02.006_bib0017","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/schbul\/sbm014","article-title":"Development of a brief scale of everyday functioning in persons with serious mental illness","volume":"33","author":"Mausbach","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2019.02.006_bib0018","doi-asserted-by":"crossref","first-page":"pyw055","DOI":"10.1093\/ijnp\/pyw055","article-title":"The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials","volume":"19","author":"McIntyre","year":"2016","journal-title":"Int. J. Neuropsychopharmacolog."},{"key":"10.1016\/j.jad.2019.02.006_bib0019","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2019.02.006_bib0020","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","article-title":"Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder","volume":"340","author":"Mork","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2019.02.006_bib0021","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.1002\/da.20343","article-title":"Do memory complaints represent impaired memory performance in patients with major depressive disorder?","volume":"25","author":"Mowla","year":"2008","journal-title":"Depress. Anxiety"},{"year":"2015","series-title":"Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression: Workshop Summary","key":"10.1016\/j.jad.2019.02.006_bib0022"},{"key":"10.1016\/j.jad.2019.02.006_bib0023","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0004867412459810","article-title":"The absence of depressive symptoms is not the presence of wellness: validation of the Clinical Positive Affect Scale","volume":"46","author":"Nierenberg","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.02.006_bib0024","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jad.2005.09.006","article-title":"Attention and executive functions in remitted major depression patients","volume":"89","author":"Paelecke-Habermann","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.02.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.jad.2019.02.006_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-0179-3-5","article-title":"Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder","volume":"3","author":"Rosa","year":"2007","journal-title":"Clin. Pract. Epidemiol. Mental Health"},{"key":"10.1016\/j.jad.2019.02.006_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2019.02.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.02.006_bib0029","article-title":"Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls","author":"Smith","year":"2017","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.jad.2019.02.006_bib0030","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1038\/s41598-017-04353-w","article-title":"Discrepancy between objective and subjective cognition in adults with major depressive disorder","volume":"7","author":"Srisurapanont","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2019.02.006_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1037\/0096-3445.121.1.15","article-title":"Studies of interference in serial verbal reactions","volume":"121","author":"Stroop","year":"1992","journal-title":"J. Exp. Psychol."},{"key":"10.1016\/j.jad.2019.02.006_bib0032","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"year":"1997","series-title":"Wechsler Adult Intelligence Scale","author":"Wechsler","key":"10.1016\/j.jad.2019.02.006_bib0033"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718313879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718313879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:21:45Z","timestamp":1759022505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718313879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":33,"alternative-id":["S0165032718313879"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.02.006","relation":{},"ISSN":["0165-0327"],"issn-type":[{"type":"print","value":"0165-0327"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}